EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis

Huiquan Wang, Jiafeng Zhang, Lei Chen, Hefei Ren, Chang Liu, Hong Kun Wu, Huiying Qiu, Juan Lu, Lin Zhou

Clinical and Experimental Medicine · 2025

DOI: 10.1007/s10238-025-01673-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Huiquan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Bortezomib, Drug Resistance, Neoplasm, Multiple Myeloma, Ferroptosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) ranks as the second most prevalent blood cancer. In the treatment of MM, resistance to proteasome inhibitors like bortezomib (BTZ) is a significant issue, and the primary regulators and mechanisms are still not completely explored. As a result, this investigation aimed to uncover essential genes and mechanisms contributing to BTZ resistance in MM. Out of 359 differentially expressed genes, DEK oncogene (DEK) was pinpointed as the key drug-resistance gene in MM through bioinformatic analysis and was found to be overexpressed in MM patients. DEK was overexpressed in BTZ-resistant cell lines, enhancing the resistance of MM cells to bortezomib. Also, the depletion of DEK mitigated bortezomib resistance in MM cells by initiating ferroptosis. The findings indicated a novel role of DEK in the resistance of MM to bortezomib, which could inform new treatment strategies for BTZ-resistant MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibDrug Resistance, NeoplasmMultiple MyelomaFerroptosisPoly-ADP-Ribose Binding ProteinsOncogene ProteinsChromosomal Proteins, Non-HistoneHumansCell Line, TumorAntineoplastic AgentsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Hematological diseaseMultiple myelomadrug resistanceferroptosis

Substanzen

BortezomibPoly-ADP-Ribose Binding ProteinsDEK protein, humanOncogene ProteinsChromosomal Proteins, Non-HistoneAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. qiuhy5@126.com.
  • Continuing Education Centre, Naval Medical University (Second Military Medical University), 800 Xiangyin Road, Shanghai, 200433, China. lujuan506@sina.com.
  • Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. lynnzhou36@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, H., Zhang, J., Chen, L., Ren, H., Liu, C., Wu, H. K., Qiu, H., Lu, J., & Zhou, L. (2025). DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01673-4

Vancouver

Wang H, Zhang J, Chen L, Ren H, Liu C, Wu HK, et al. DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01673-4

BibTeX
@article{Wang2025,
  author = {Wang, Huiquan and Zhang, Jiafeng and Chen, Lei and Ren, Hefei and Liu, Chang and Wu, Hong Kun and Qiu, Huiying and Lu, Juan and Zhou, Lin},
  title = {DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis},
  journal = {Clinical and Experimental Medicine},
  year = {2025},
  doi = {10.1007/s10238-025-01673-4}
}
Kostenlos starten →